



Press release

Quantitative proteomics for cancer diagnosis

1204 characters.

Contact: Markus Fischer. info@polyquant.com

This press release is also available in electronic form at www.polyquant.com/presse.

Regensburg, April 01, 2008 – Within the context of the 7th EU framework program, an international research cooperation of six academic institutions and two companies has started an initiative for the identification and validation of biomarkers for the clinical diagnosis of bladder cancer. The 4-year project aims at applying modern methods of quantitative proteomics to clinical problems. PolyQuant GmbH is involved in the project via its parent company, Entelechon GmbH, and will contribute its protein analysis technology QconCAT for the absolute quantification of biomarker candidates.

With the help of QconCAT, a large panel of up to 100 proteins can be quantified in a single analysis. The approach detects quantitative differences between relevant target proteins of healthy subjects and patients. This data will provide important insights into the qualification of the analyzed proteins as biomarkers for cancer diagnosis.

In addition to the immediate aim of the DeCanBio project – the diagnosis of bladder cancer – the projected research will validate quantitative proteomics as a technological basis for the targeted, sensitive and predictive diagnosis, especially in the field of tumor diseases.

About PolyQuant GmbH

PolyQuant GmbH has been founded in 2007, with the aim to provide targeted solutions for quantitative proteomics, protein analysis and protein expression. The main field of business is the proteome analysis, using the QconCAT method. The development of QconCAT has been funded by the BioChancePlus program. PolyQuant is a spin-off of Entelechon GmbH, a company who has been on the market of gene synthesis and bioinformatics since 1999.

Contact

PolyQuant GmbH
St. Veit-Weg 2
93051 Regensburg
Germany
Tel. +49 941.9468.360
Fax +49 941.9468.366
info@polyquant.com
www.polyquant.com